All In MedTech

FDA Clearance Tracker · P160054-S039

HeartMate 3™ Left Ventricular Assist System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Mar 24, 2022 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Mar 24, 2022

Approved

Time to decision

178 days

Received Sep 27, 2021. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P160054-S039
Device name
HeartMate 3™ Left Ventricular Assist System
Applicant location
Pleasanton, CA
Received
Sep 27, 2021
Decided
Mar 24, 2022
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - PAS
Original approval
P160054

Device type

Device class
Class III
Specialty
Cardiology

Every decision under product code DSQ

FDA's approval statement

As written in FDA's record.

Approval for various updates to the Instructions for Use to add the final clinical results of the Long-Term Durability Cohort of the pivotal trial and of the post-approval study entitled "Continued Follow-up of the Continued Access Cohort."

Source documents

Other decisions for ABBOTT MEDICAL

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.